AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans

Contributed by: PR Newswire

Tags

ADJANE-new

More Like This

AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans

GlobeNewswire associated0

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2

CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea

GlobeNewswire associated0

CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea

Business Wire logo

Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae

Business Wire logo

Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease

DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia